Non-alcoholic fatty liver disease
Conditions
Interventions
Control group:Yuan Qing placebo specific dosage refer to the instructions. Every 30 days for a course of treatment, a total of 3 courses.
Case group:Yuan Qing specific dosage refer to the instructions. Every 30 days for a course of treatment, a total of 3 courses.
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: ? Meet the diagnostic criteria for nonalcoholic fatty liver disease (see Guidelines for Prevention and Treatment of nonalcoholic Fatty Liver Disease); ? Not less than 18 years old and not more than 60 years old; ? Agree and sign informed consent.
Exclusion criteria
Exclusion criteria: ? Patients with serious diseases of the heart, kidney, brain, lung, blood, digestive system or mental illness; ? Pregnant or lactating women; ? Situations where other clinicians consider it inappropriate to participate in clinical research; ?Patients with a significant history of alcohol consumption (AUDIT questionnaire) or whose alcohol consumption cannot be quantified; ?Long-term use (more than 2 weeks) in the past year of drugs that can cause liver steatosis or steatohepatitis (glucocorticoids, tetracycline, anabolic steroids, valproic acid, salicylate, tamoxifen), or use of drugs with significant liver toxicity; ?Suffering from other liver diseases (such as viral hepatitis, immune hepatitis, drug-induced hepatitis, etc.) or have received a liver transplant; ?Suffering from immune system disease, cancer or kidney disease; ?Suffers from diabetes; ?Patients who are currently enrolled in another clinical trial or have received an investigational drug within the past 60 days; ?MRI is not possible due to metal equipment, claustrophobia or other reasons; ?Changes in diet, exercise habits, or body weight in the last three months (5% or more).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver lipid contents; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum lipid parameter;visceral fat area;fatty liver (FL) index;HOMA-IR; | — |
Countries
China
Contacts
Public ContactQinghua Yin
West China Hospital, Sichuan University
Outcome results
None listed